Janux Therapeutics Stock Analysis

Janux Stock Analysis Notes

About 95.0% of the company shares are owned by institutional investors. The book value of Janux Therapeutics was currently reported as 12.54. The company recorded a loss per share of 1.17. Janux Therapeutics had not issued any dividends in recent years. Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager platform technology to treat patients suffering from cancer. The company was incorporated in 2017 and is headquartered in La Jolla, California. Janux Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 56 people. To learn more about Janux Therapeutics call David Campbell at 858 751 4493 or check out https://www.januxrx.com.

Janux Therapeutics Investment Alerts

Janux Therapeutics Upcoming and Recent Events

Janux Largest EPS Surprises

View All Earnings Estimates

Janux Therapeutics Environmental, Social, and Governance (ESG) Scores

Janux Stock Institutional Investors

Note, although Janux Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Janux Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.64 B.

Janux Profitablity

Management Efficiency

Janux Therapeutics has return on total asset (ROA) of (0.0993) % which means that it has lost $0.0993 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1205) %, meaning that it created substantial loss on money invested by shareholders. Janux Therapeutics' management efficiency ratios could be used to measure how well Janux Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.16 in 2024. Return On Capital Employed is likely to rise to -0.19 in 2024. At this time, Janux Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 32.7 M in 2024, whereas Total Assets are likely to drop slightly above 251.1 M in 2024.

Technical Drivers

As of the 26th of November, Janux Therapeutics retains the Risk Adjusted Performance of 0.0661, market risk adjusted performance of 0.2582, and Downside Deviation of 2.66. Janux Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.

Janux Therapeutics Price Movement Analysis

Janux Therapeutics Insider Trading Activities

Janux Therapeutics Outstanding Bonds

Janux Therapeutics Predictive Daily Indicators

Janux Therapeutics Corporate Filings

Janux Therapeutics Forecast Models

Janux Therapeutics' time-series forecasting models are one of many Janux Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Janux Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Janux Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Janux shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Janux Therapeutics. By using and applying Janux Stock analysis, traders can create a robust methodology for identifying Janux entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Janux analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Janux analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Janux Therapeutics stock analysis indicators help investors evaluate how Janux Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Janux Therapeutics shares will generate the highest return on investment. By understating and applying Janux Therapeutics stock analysis, traders can identify Janux Therapeutics position entry and exit signals to maximize returns.

When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.